» Articles » PMID: 38223779

Acute, Treatment-Naïve Branch Retinal Vein Occlusion in Younger Individuals: Risk Factors and Clinical Outcomes

Overview
Publisher Sage Publications
Date 2024 Jan 15
PMID 38223779
Authors
Affiliations
Soon will be listed here.
Abstract

To compare the risk factors and clinical outcomes in patients younger than 50 years with acute, treatment-naïve branch retinal vein occlusion (BRVO) with outcomes in patients 50 years or older. Patients diagnosed with acute, treatment-naïve BRVO at Duke Eye Center over a 9.5-year period who had BRVO with onset 3 months or less before presentation, BRVO with macular involvement, and 12 months or more of follow-up were included. Demographic data, presenting clinical features, risk factors, treatment patterns, and clinical outcomes were extracted during a retrospective review of medical records. Of 302 patients identified, 23 were younger than 50 years (younger group) and 279 were 50 years or older (older group). Compared with older patients, younger patients had similar rates of hypertension ( = .275), diabetes mellitus ( = 1.000), smokers ( = .787), and open-angle glaucoma ( = .628). The younger group had a lower rate of hyperlipidemia than the older group (35% vs 59%) ( = .028). The 2 groups had similar presenting logMAR visual acuities (VAs) in the BRVO eye ( = .131). At the final follow-up, younger patients had significantly better logMAR VA in the BRVO-affected eye than older patients (mean 0.51 ± 0.65 vs 1.01 ± 1.20) ( = .016). The 2 groups had similar treatment burdens at 1 year ( = .516) and at the final follow-up ( = .782). Younger patients with acute, treatment-naïve BRVO have similar risk factors and treatment patterns as older patients, except for a lower rate of hyperlipidemia. Younger patients with BRVO may have similar presenting VA as older BRVO patients but better final VA, suggesting that age may be a potential prognostic factor.

Citing Articles

Systemic Risk Factors in Branch Retinal Vein Occlusion: a Comprehensive Review.

Garnavou-Xirou C, Bontzos G, Smoustopoulos G, Velissaris S, Papadopoulos A, Georgopoulos E Maedica (Bucur). 2024; 19(2):380-387.

PMID: 39188832 PMC: 11345058. DOI: 10.26574/maedica.2024.19.2.380.


From the Editor-in-Chief.

Murray T J Vitreoretin Dis. 2024; 8(1):5-8.

PMID: 38223765 PMC: 10786075. DOI: 10.1177/24741264231222514.

References
1.
Christoffersen N, Larsen M . Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999; 106(11):2054-62. DOI: 10.1016/S0161-6420(99)90483-9. View

2.
Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojjanakul W, Yospaiboon Y . Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol. 2017; 11:441-447. PMC: 5328302. DOI: 10.2147/OPTH.S128341. View

3.
Rosada A, Kassner U, Weidemann F, Konig M, Buchmann N, Steinhagen-Thiessen E . Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. Lipids Health Dis. 2020; 19(1):92. PMC: 7227351. DOI: 10.1186/s12944-020-01277-9. View

4.
Cugati S, Wang J, Rochtchina E, Mitchell P . Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol. 2006; 124(5):726-32. DOI: 10.1001/archopht.124.5.726. View

5.
Rothman A, Thomas A, Khan K, Fekrat S . CENTRAL RETINAL VEIN OCCLUSION IN YOUNG INDIVIDUALS: A Comparison of Risk Factors and Clinical Outcomes. Retina. 2018; 39(10):1917-1924. DOI: 10.1097/IAE.0000000000002278. View